IRIDEX CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IRIDEX CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 30, 2017 | $10.24M | Mar 14, 2018 |
| FY2017 | Sep 30, 2017 | $10.87M | Mar 14, 2018 |
| FY2017 | Jul 1, 2017 | $10.00M | Mar 14, 2018 |
| FY2017 | Apr 1, 2017 | $10.48M | Mar 14, 2018 |
| FY2017 | Dec 31, 2016 | $12.53M | Mar 14, 2018 |
| FY2017 | Oct 1, 2016 | $9.79M | Mar 14, 2018 |
| FY2017 | Jul 2, 2016 | $11.91M | Mar 14, 2018 |
| FY2017 | Apr 2, 2016 | $11.93M | Mar 14, 2018 |
| FY2017 | Jan 2, 2016 | $41.76M | Mar 14, 2018 |
| FY2016 | Jan 3, 2015 | $42.81M | Mar 15, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $52.68M | Apr 2, 2026 |
| FY2026 | Dec 28, 2024 | $48.67M | Apr 2, 2026 |
| FY2024 | Dec 30, 2023 | $51.87M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $56.97M | Mar 29, 2024 |
| FY2022 | Jan 1, 2022 | $53.90M | Mar 9, 2023 |
| FY2021 | Jan 2, 2021 | $36.35M | Mar 15, 2022 |
| FY2021 | Dec 28, 2019 | $43.45M | Mar 23, 2021 |
| FY2019 | Dec 29, 2018 | $42.60M | Mar 13, 2020 |
| FY2018 | Dec 30, 2017 | $41.59M | Mar 29, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $19.23M | Apr 2, 2026 |
| FY2026 | Dec 28, 2024 | $19.50M | Apr 2, 2026 |
| FY2024 | Dec 30, 2023 | $21.81M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $25.37M | Mar 29, 2024 |
| FY2022 | Jan 1, 2022 | $22.83M | Mar 9, 2023 |
| FY2021 | Jan 2, 2021 | $15.56M | Mar 15, 2022 |
| FY2021 | Dec 28, 2019 | $17.94M | Mar 23, 2021 |
| FY2019 | Dec 29, 2018 | $17.47M | Mar 13, 2020 |
| FY2017 | Dec 30, 2017 | $2.17M | Mar 14, 2018 |
| FY2017 | Sep 30, 2017 | $4.37M | Mar 14, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | ($4.44M) | Apr 2, 2026 |
| FY2026 | Dec 28, 2024 | ($8.91M) | Apr 2, 2026 |
| FY2024 | Dec 30, 2023 | ($9.57M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($7.55M) | Mar 29, 2024 |
| FY2022 | Jan 1, 2022 | ($5.23M) | Mar 9, 2023 |
| FY2021 | Jan 2, 2021 | ($6.33M) | Mar 15, 2022 |
| FY2021 | Dec 28, 2019 | ($8.81M) | Mar 23, 2021 |
| FY2019 | Dec 29, 2018 | ($12.81M) | Mar 13, 2020 |
| FY2017 | Dec 30, 2017 | ($5.16M) | Mar 14, 2018 |
| FY2017 | Sep 30, 2017 | ($3.10M) | Mar 14, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | ($2.57M) | Apr 2, 2026 |
| FY2026 | Dec 28, 2024 | ($8.30M) | Apr 2, 2026 |
| FY2024 | Dec 30, 2023 | ($10.01M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($7.54M) | Mar 29, 2024 |
| FY2022 | Jan 1, 2022 | ($7.53M) | Mar 9, 2023 |
| FY2021 | Jan 2, 2021 | ($6.58M) | Mar 15, 2022 |
| FY2021 | Dec 28, 2019 | ($8.97M) | Mar 23, 2021 |
| FY2019 | Dec 29, 2018 | ($12.87M) | Mar 13, 2020 |
| FY2017 | Dec 30, 2017 | ($5.22M) | Mar 14, 2018 |
| FY2017 | Sep 30, 2017 | ($3.07M) | Mar 14, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $3.67M | Apr 2, 2026 |
| FY2026 | Dec 28, 2024 | $5.45M | Apr 2, 2026 |
| FY2024 | Dec 30, 2023 | $6.83M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $7.18M | Mar 29, 2024 |
| FY2022 | Jan 1, 2022 | $6.87M | Mar 9, 2023 |
| FY2021 | Jan 2, 2021 | $3.28M | Mar 15, 2022 |
| FY2021 | Dec 28, 2019 | $3.68M | Mar 23, 2021 |
| FY2019 | Dec 29, 2018 | $4.01M | Mar 13, 2020 |
| FY2017 | Dec 30, 2017 | $1.28M | Mar 14, 2018 |
| FY2017 | Sep 30, 2017 | $1.43M | Mar 14, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | ($2.12M) | Apr 2, 2026 |
| FY2026 | Dec 28, 2024 | ($7.29M) | Apr 2, 2026 |
| FY2024 | Dec 30, 2023 | ($6.75M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($9.52M) | Mar 29, 2024 |
| FY2022 | Jan 1, 2022 | $8.22M | Mar 9, 2023 |
| FY2021 | Jan 2, 2021 | ($3.24M) | Mar 15, 2022 |
| FY2021 | Dec 28, 2019 | ($7.91M) | Mar 23, 2021 |
| FY2019 | Dec 29, 2018 | ($10.03M) | Mar 13, 2020 |
| FY2018 | Dec 30, 2017 | ($3.57M) | Mar 29, 2019 |
| FY2015 | Jan 2, 2016 | ($593.0K) | Mar 31, 2016 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $143.0K | Apr 2, 2026 |
| FY2026 | Dec 28, 2024 | $13.0K | Apr 2, 2026 |
| FY2024 | Dec 30, 2023 | $109.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $286.0K | Mar 29, 2024 |
| FY2022 | Jan 1, 2022 | $213.0K | Mar 9, 2023 |
| FY2021 | Jan 2, 2021 | $97.0K | Mar 15, 2022 |
| FY2021 | Dec 28, 2019 | $128.0K | Mar 23, 2021 |
| FY2019 | Dec 29, 2018 | $440.0K | Mar 13, 2020 |
| FY2018 | Dec 30, 2017 | $575.0K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $1.06M | Mar 14, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $29.15M | Apr 2, 2026 |
| FY2026 | Dec 28, 2024 | $29.14M | Apr 2, 2026 |
| FY2024 | Dec 30, 2023 | $34.44M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $42.29M | Mar 29, 2024 |
| FY2022 | Jan 1, 2022 | $48.69M | Mar 9, 2023 |
| FY2021 | Jan 2, 2021 | $27.97M | Mar 15, 2022 |
| FY2021 | Dec 28, 2019 | $34.81M | Mar 23, 2021 |
| FY2019 | Dec 29, 2018 | $41.67M | Mar 13, 2020 |
| FY2018 | Dec 30, 2017 | $41.65M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $48.14M | Mar 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $24.23M | Apr 2, 2026 |
| FY2026 | Dec 28, 2024 | $27.04M | Apr 2, 2026 |
| FY2024 | Dec 30, 2023 | $24.91M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $25.06M | Mar 29, 2024 |
| FY2022 | Jan 1, 2022 | $25.39M | Mar 9, 2023 |
| FY2021 | Jan 2, 2021 | $10.60M | Mar 15, 2022 |
| FY2021 | Dec 28, 2019 | $12.11M | Mar 23, 2021 |
| FY2019 | Dec 29, 2018 | $11.71M | Mar 13, 2020 |
| FY2018 | Dec 30, 2017 | $11.12M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $8.98M | Mar 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $4.92M | Apr 2, 2026 |
| FY2026 | Dec 28, 2024 | $2.10M | Apr 2, 2026 |
| FY2026 | Dec 30, 2023 | $9.52M | Apr 2, 2026 |
| FY2024 | Dec 31, 2022 | $17.23M | Mar 27, 2025 |
| FY2023 | Jan 1, 2022 | $23.30M | Mar 29, 2024 |
| FY2022 | Jan 2, 2021 | $17.37M | Mar 9, 2023 |
| FY2021 | Dec 28, 2019 | $22.71M | Mar 15, 2022 |
| FY2021 | Dec 29, 2018 | $29.96M | Mar 23, 2021 |
| FY2019 | Dec 30, 2017 | $30.52M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $39.16M | Mar 29, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $965.0K | Apr 2, 2026 |
| FY2026 | Dec 28, 2024 | $965.0K | Apr 2, 2026 |
| FY2024 | Dec 30, 2023 | $965.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $965.0K | Mar 29, 2024 |
| FY2022 | Jan 1, 2022 | $965.0K | Mar 9, 2023 |
| FY2022 | Mar 31, 2021 | $400.0K | Mar 9, 2023 |
| FY2021 | Jan 2, 2021 | $533.0K | Mar 15, 2022 |
| FY2021 | Dec 28, 2019 | $533.0K | Mar 23, 2021 |
| FY2019 | Dec 29, 2018 | $533.0K | Mar 13, 2020 |
| FY2018 | Dec 30, 2017 | $533.0K | Mar 29, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | ($92.45M) | Apr 2, 2026 |
| FY2026 | Dec 28, 2024 | ($88.01M) | Apr 2, 2026 |
| FY2024 | Dec 30, 2023 | ($79.04M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($69.72M) | Mar 29, 2024 |
| FY2022 | Jan 1, 2022 | ($62.17M) | Mar 9, 2023 |
| FY2021 | Jan 2, 2021 | ($56.94M) | Mar 15, 2022 |
| FY2021 | Dec 28, 2019 | ($50.62M) | Mar 23, 2021 |
| FY2019 | Dec 29, 2018 | ($41.80M) | Mar 13, 2020 |
| FY2018 | Dec 30, 2017 | ($28.99M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($16.12M) | Mar 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $6.03M | Apr 2, 2026 |
| FY2026 | Dec 28, 2024 | $2.39M | Apr 2, 2026 |
| FY2024 | Dec 30, 2023 | $7.03M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $13.92M | Mar 29, 2024 |
| FY2022 | Jan 1, 2022 | $23.85M | Mar 9, 2023 |
| FY2021 | Jan 2, 2021 | $11.63M | Mar 15, 2022 |
| FY2021 | Dec 28, 2019 | $12.65M | Mar 23, 2021 |
| FY2019 | Dec 29, 2018 | $21.19M | Mar 13, 2020 |
| FY2018 | Dec 30, 2017 | $21.71M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $23.75M | Mar 14, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Dec 28, 2024 | $1.00M | Apr 2, 2026 |
| FY2021 | Jan 2, 2021 | $1.25M | Mar 15, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | 0 | Apr 2, 2026 |
| FY2026 | Dec 28, 2024 | 0 | Apr 2, 2026 |
| FY2024 | Dec 30, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Jan 1, 2022 | 0 | Mar 9, 2023 |
| FY2021 | Jan 2, 2021 | 0 | Mar 15, 2022 |
| FY2021 | Dec 28, 2019 | 0 | Mar 23, 2021 |
| FY2019 | Dec 29, 2018 | (1) | Mar 13, 2020 |
| FY2017 | Dec 30, 2017 | 0 | Mar 14, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Mar 14, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | 0 | Apr 2, 2026 |
| FY2026 | Dec 28, 2024 | 0 | Apr 2, 2026 |
| FY2024 | Dec 30, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Jan 1, 2022 | 0 | Mar 9, 2023 |
| FY2021 | Jan 2, 2021 | 0 | Mar 15, 2022 |
| FY2021 | Dec 28, 2019 | 0 | Mar 23, 2021 |
| FY2019 | Dec 29, 2018 | (1) | Mar 13, 2020 |
| FY2017 | Dec 30, 2017 | 0 | Mar 14, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Mar 14, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | 17.31M | Apr 2, 2026 |
| FY2026 | Dec 28, 2024 | 16.64M | Apr 2, 2026 |
| FY2024 | Dec 30, 2023 | 16.25M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 15.99M | Mar 29, 2024 |
| FY2022 | Jan 1, 2022 | 15.88M | Mar 9, 2023 |
| FY2021 | Jan 2, 2021 | 13.90M | Mar 15, 2022 |
| FY2021 | Dec 28, 2019 | 13.79M | Mar 23, 2021 |
| FY2019 | Dec 29, 2018 | 13.60M | Mar 13, 2020 |
| FY2018 | Dec 30, 2017 | 11.60M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 11.30M | Mar 14, 2018 |